Safety considerations for cereblon-recruiting targeted protein degraders
Helen Garside(AstraZeneca (United Kingdom)), James D. Sidaway(National University of Singapore), Lise I. Loberg(AbbVie (United States)), Zoran Ranković(St. Jude Children's Research Hospital), Aishwarya Rengarajan(United States Military Academy), Ruth Roberts(Redx Pharma (United Kingdom)), Tejas S. Lahoti(Optimum Therapeutics (United States)), Mira Pavkovic(Bayer (Germany)), Lucilia Pereira Mouriès(Health and Environmental Sciences Institute), Mikael E. Pedersen(Novo Nordisk (Denmark)), Ronald L. Wange(Center for Drug Evaluation and Research), Kaushik Datta(Bristol-Myers Squibb (Germany)), Neil Vargesson(University of Aberdeen), Axel Vicart(Novartis (Switzerland)), Davorka Messmer(Nurix (United States)), Raegan O'Lone(Health and Environmental Sciences Institute), Renee R. Hukkanen(Amgen (United States)), N Ketter(Boehringer Ingelheim (Germany)), Timothy Pastoor(Zen Bio (United States)), Amy Aslamkhan(United States Military Academy), Lyn H. Jones(Harvard University), Gina Yanochko-Hoffman(Johnson & Johnson (United States)), Danette L. Daniels(Foghorn Therapeutics (United States))
Cited by 2
Related Papers
Thalidomide‐induced teratogenesis: History and mechanisms
|Birth Defects Research Part C Embryo Today Reviews|2015|873
ISO-1 Binding to the Tautomerase Active Site of MIF Inhibits Its Pro-inflammatory Activity and Increases Survival in Severe Sepsis
|Journal of Biological Chemistry|2005|316
TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant
|Journal of Translational Medicine|2014|98
The TIP60 Complex Is a Conserved Coactivator of HIF1A
|Cell Reports|2016|97